Prime Medicine, Inc.
PRME
$3.27
-$0.03-0.91%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -198.37M | -201.14M | -197.34M | -199.28M | -202.01M |
| Total Depreciation and Amortization | 7.48M | 7.32M | 7.16M | 6.84M | 6.51M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 34.67M | 36.60M | 38.75M | 33.67M | 37.95M |
| Change in Net Operating Assets | -187.00K | -5.34M | 42.36M | 58.83M | 53.53M |
| Cash from Operations | -156.42M | -162.56M | -109.06M | -99.94M | -104.02M |
| Capital Expenditure | -2.32M | -4.53M | -6.03M | -7.06M | -7.39M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -15.31M | -104.23M | -82.81M | 60.69M | 65.14M |
| Cash from Investing | -17.63M | -108.76M | -88.84M | 53.62M | 57.75M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 139.91M | 139.51M | 138.95M | 38.71M | 38.55M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 6.00M | 12.00M | 12.00M | 6.00M | 6.00M |
| Cash from Financing | 145.91M | 151.51M | 150.95M | 44.71M | 44.55M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.14M | -119.82M | -46.95M | -1.60M | -1.72M |